Cantor Fitzgerald Weighs in on Pfizer FY2026 Earnings

Pfizer Inc. (NYSE:PFE - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for Pfizer in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the biopharmaceutical company will post earnings per share of $3.10 for the year. Cantor Fitzgerald currently has a "Neutral" rating and a $24.00 price target on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year.

PFE has been the subject of several other reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Performance

PFE stock traded up $0.22 during trading on Tuesday, reaching $24.52. The company had a trading volume of 15,212,869 shares, compared to its average volume of 40,937,157. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a market cap of $139.38 billion, a price-to-earnings ratio of 17.40, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The firm has a 50-day simple moving average of $22.93 and a 200-day simple moving average of $24.98.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.02%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. First Hawaiian Bank grew its holdings in shares of Pfizer by 6.9% during the first quarter. First Hawaiian Bank now owns 54,455 shares of the biopharmaceutical company's stock worth $1,380,000 after buying an additional 3,531 shares during the last quarter. Modern Wealth Management LLC raised its position in Pfizer by 41.4% during the 1st quarter. Modern Wealth Management LLC now owns 44,785 shares of the biopharmaceutical company's stock worth $1,135,000 after buying an additional 13,104 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Pfizer by 37.8% in the first quarter. Jones Financial Companies Lllp now owns 2,516,211 shares of the biopharmaceutical company's stock valued at $63,441,000 after buying an additional 690,259 shares in the last quarter. Strs Ohio purchased a new position in Pfizer in the 1st quarter valued at about $49,968,000. Finally, Wealth Management Associates Inc. lifted its stake in shares of Pfizer by 10.2% during the first quarter. Wealth Management Associates Inc. now owns 54,720 shares of the biopharmaceutical company's stock valued at $1,387,000 after buying an additional 5,053 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.